SpecialtiesGerhard Bauer 
Clinical/Research Interests
Gerhard Bauer is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures. In addition to GMP design and construction expertise, Bauer also has extensive experience in the field of gene and cell therapy, having spent two decades developing novel clinical applications to improve medical outcomes for life-threatening illnesses.
He also has investigated potential therapies for HIV, replacing the devastated immune system of an HIV-infected patient with cells that have been engineered to resist the virus. Bauer came to the UC Davis Health System in 2006 after designing and directing a state-of-the-art GMP laboratory at Washington University in St. Louis.
Title:
Specialty:
Center/Program Affiliation:
Address:
2921 Stockton Blvd.
Sacramento, CA 95817
Other Languages:
Education:
Wieselburg, Austria
B.S.
Professional Memberships:
UC Davis Institutional Biosafety Committee
UC Davis Medical School Admissions Committee
UC Davis Translational Research Integration and Compliance Committee
Select Recent Publications:
Kambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J, Lindsey M, Fury B, Bauer G, Nolta JA, Anderson JS. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther. 2011 Mar;19(3):584-93. Epub 2010 Nov 30.
Jung Y, Bauer G, Nolta JA. Induced Pluripotent Stem Cell - Derived Mesenchymal Stem Cells: Progress Toward Safe Clinical Products. Stem Cells. 2011 Sep 2. doi: 10.1002/stem.727. [Epub ahead of print]
Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, Bauer G, Nolta JA. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev. 2010 Sep 30;62(12):1167-74. Epub 2010 Oct 13. Review.
Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2010 Nov;5(6):933-46. Review.
Pre-integration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCRS shRNA, and a TAR decoy. Anderson JS, Javien J, Nolta JA, Bauer G. Mol Ther. 2009 Dec; 17(12):2103-14. Epub 2009 Aug 18.
Specific Transduction of HIV-Susceptible Cells for CCR5 Knockdown and Resistance to HIV Infection: A Novel Method for Targeted Gene Therapy and Intracellular Immunization. Anderson JS, Walker J, Nolta JA, Bauer G. J Acquir Immune Defic Syndr. 2009 Jul 10. (Epub ahead of print)
In Vivo Biosafety Model to Assess Risk of Adverse Events from Retroviral and Lentiviral Vectors. G Bauer, M Dao, S Case, P Herrbrich, J Arevalo, T Meyerrose, X Wang, S Csik, D Skelton, DB Kohn, and J Nolta. Mol Ther. 2008; 16:1308-1315, Epub 2008 May 06.
Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, Bonyhadi ML, Berenson RJ, Prior JL, Piwnica-Worms D, Nolta JA, DiPersio JF. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol. 2007 Dec;35(12):1823-38. Epub 2007 Aug 30.
Nervi B, Rettig M, Ritchey J, Wang H, Bauer G, Walker J, Bonyhadi M, Berenson R, Herrbrich P, Nolta J, Dipersio. Naive and ex-vivo activated human T cells generate consistent engraftment and lethal Graft versus Host Disease in NOD SCID beta2m null mice: a novel xenogeneic GvHD model. Experimental Hematology 2006.
Dao, M, Case, S, Bauer, G, Arevalo, J, Meyerrose, T, Wang, X, Csik, S. Skelton, D, Crooks, G, Kohn, DB, Nolta, J. In Vivo Biosafety Model to Assess Risk of Recombinant Vector Production and Insertional Mutagenesis from Retroviral and Lentiviral Vectors. Human Gene Therapy December 2005.
